Magnetic Resonance Program, Huntington Medical Research Institutes, Pasadena, California, United States of America.
Fuller Graduate School of Psychology, Pasadena, California, United States of America.
PLoS One. 2021 Jul 22;16(7):e0254332. doi: 10.1371/journal.pone.0254332. eCollection 2021.
We hypothesized that automated assessment of brain volumes on MRI can predict presence of cerebrospinal fluid abnormal ß-amyloid42 and Tau protein levels and thus serve as a useful screening test for possible Alzheimer's disease. 113 participants ranging from cognitively healthy to Alzheimer's disease underwent MRI exams to obtain measurements of hippocampus, prefrontal cortex, precuneus, parietal cortex, and occipital lobe volumes. A non-exclusive subset (n = 107) consented to lumbar punctures to obtain cerebrospinal fluid for ß-amyloid42 and Tau protein assessment including cognitively health (n = 75), mild cognitively impaired (n = 22), and Alzheimer's disease (n = 10). After adjustment for false discovery rate, ß-amyloid42 was significantly associated with volumes in the hippocampus (p = 0.043), prefrontal cortex (p = 0.010), precuneus (p = 0.024), and the posterior cingulate (p = 0.002). No association between Tau levels and regional brain volume survived multiple test correction. Secondary analysis was performed to determine associations between MRI brain volumes and CSF protein levels to neuropsychological impairment. A non-exclusive subset (n = 96) including cognitively healthy (n = 72), mild cognitively impaired (n = 21), and Alzheimer's disease (n = 3) participants underwent Stroop Interference and Boston Naming neuropsychological testing. A higher score on the Boston Naming Test was optimally predicted in a selective regression model by greater hippocampus volume (p = 0.002), a higher ratio of ß-amyloid42 to Tau protein levels (p < 0.001), greater posterior cingulate volume (p = 0.0193), age (p = 0.0271), and a higher education level (p = 0.002). A better performance on the Stroop Interference Test was optimally predicted by greater hippocampus volume (p = 0.0003) and a higher education level (p < 0.001). Lastly, impaired cognitive status (mild cognitive impairment and Alzheimer's Disease) was optimally predicted in a selective regression model by a worse performance on the Stroop Interference Test (p < 0.001), a worse performance on the Boston Naming Test (p < 0.001), along with lower prefrontal cortex volume (p = 0.002) and lower hippocampus volume (p = 0.007).
我们假设 MRI 上的脑容量自动评估可以预测脑脊液中异常的 β-淀粉样蛋白 42 和 Tau 蛋白水平的存在,从而成为一种有用的阿尔茨海默病筛查测试。113 名参与者从认知健康到阿尔茨海默病不等,接受了 MRI 检查,以获得海马体、前额叶皮层、楔前叶、顶叶皮层和枕叶体积的测量值。一个非排他子集(n = 107)同意进行腰椎穿刺,以获得 β-淀粉样蛋白 42 和 Tau 蛋白评估的脑脊液,包括认知健康(n = 75)、轻度认知障碍(n = 22)和阿尔茨海默病(n = 10)。在调整了假发现率后,β-淀粉样蛋白 42 与海马体(p = 0.043)、前额叶皮层(p = 0.010)、楔前叶(p = 0.024)和后扣带回(p = 0.002)的体积显著相关。Tau 水平与脑区体积之间的关联在多次检验校正后没有幸存下来。进行了二次分析以确定 MRI 脑容量与 CSF 蛋白水平与神经心理学损伤之间的关联。一个非排他子集(n = 96),包括认知健康(n = 72)、轻度认知障碍(n = 21)和阿尔茨海默病(n = 3)参与者,接受了 Stroop 干扰和波士顿命名神经心理学测试。在选择性回归模型中,较高的波士顿命名测试分数最佳预测了海马体体积(p = 0.002)、β-淀粉样蛋白 42 与 Tau 蛋白水平的比值较高(p < 0.001)、后扣带回体积较大(p = 0.0193)、年龄(p = 0.0271)和较高的教育水平(p = 0.002)。Stroop 干扰测试的更好表现最佳预测了海马体体积(p = 0.0003)和较高的教育水平(p < 0.001)。最后,在选择性回归模型中,认知状态受损(轻度认知障碍和阿尔茨海默病)最佳预测为 Stroop 干扰测试表现较差(p < 0.001)、波士顿命名测试表现较差(p < 0.001),以及前额叶皮层体积较低(p = 0.002)和海马体体积较低(p = 0.007)。